Powerful Psychedelic Drug Gains New Notice as an Opioid Addiction Therapy – The New York Times

New research is stirring interest in ibogaine, which appears to help ease the agony of detox and prevent relapse. Used in other countries, it remains illegal in the U.S.
Yellow iboga fruit (Tabernanthe iboga). Credit…Alamy
Supported by

Andrew Jacobs, who writes about psychedelic medicine, reported from Louisville, Ky.
Ibogaine, a formidable psychedelic made from the root of a shrub native to Central Africa, is not for the timid. It unleashes a harrowing trip that can last more than 24 hours, and the drug can cause sudden cardiac arrest and death.
But scientists who have studied ibogaine have reported startling findings. According to a number of small studies, between a third and two-thirds of the people who were addicted to opioids or crack cocaine and were treated with the compound in a therapeutic setting were effectively cured of their habits, many after just a single session.
Ibogaine appears to provide two seemingly distinct benefits. It quells the agony of opioid withdrawal and cravings and then gives patients a born-again-style zeal for sobriety.
Now, after decades in the shadows, and with opioid overdose deaths exceeding 100,000 a year, ibogaine is drawing a surge of fresh interest from researchers who believe it has the potential to treat opioid use disorder.
“It’s not an exaggeration to say that ibogaine saved my life, allowed me to make amends with the people I hurt and helped me learn to love myself again,” said Jessica Blackburn, 37, who is recovering from heroin addiction and has been sober for eight years. “My biggest frustration is that more people don’t have access to it.”
That’s because ibogaine is illegal in the United States. Patients have to go abroad for ibogaine therapy, often at unregulated clinics that provide little medical oversight.
We are having trouble retrieving the article content.
Please enable JavaScript in your browser settings.
Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.
Thank you for your patience while we verify access.
Already a subscriber? Log in.
Want all of The Times? Subscribe.
Advertisement

source

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *